StockData
EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Evaxion A/S

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026
$3.33+0.50 (+17.67%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

Evaxion A/S revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Evaxion A/S does not break out revenue by segment, region or product in the tagged data of its filings for this period type.